ADRB2 cancer markers

• US 8,058,003 B2
• Filed: 01/18/2008
• Issued: 11/15/2011
• Est. Priority Date: 01/19/2007
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Chinnaiyan, Arul M., Mehra, Rohit, Yu, Jindan
• Primary Examiner(s): Strzelecka; Teresa E
• Application Number:
  US12/016,498
• Publication Number:
  US 20090075833A1
• Time in Patent Office: 1,397 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.

Claims

1. A method for identifying metastatic prostate cancer in a patient, comprising detecting underexpression of Adrenergic Receptor, Beta 2 (ADRB2) in a sample from the patient using an in vitro assay compared to expression of ADRB2 in a sample from a patient not diagnosed with prostate cancer, wherein detecting underexpression identifies metastatic prostate cancer in said patient.

2. The method of claim 1, wherein said sample is a biopsy sample.

3. The method of claim 1, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 nucleic acid in said sample.

4. The method of claim 3, wherein said detecting the level of ADRB2 nucleic acid in said sample comprises detecting the level of ADRB2 mRNA in said sample.

5. The method of claim 4, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises a detection technique selected from the group consisting of microarray analysis, reverse transcriptase PCR, quantitative reverse transcriptase PCR, and hybridization analysis.

6. The method of claim 1, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 polypeptide in said sample.